Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: Long-term follow-up of a pilot study from the Wisconsin Oncology Network

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1675-1680

  Kenkre, Vaishalee P ^a   Long, Walter L ^a   Eickhoff, Jens C ^b   Blank, Jules H ^c   McFarland, Thomas A ^d   Bottner, Wayne ^e   Rezazedeh, Hamied ^f   Werndli, Jae E ^a   Bailey, Howard H ^a   Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Green Bay Oncology   (United States)

^d University of Wisconsin Health   (United States)

^e GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^f Aspirus Cancer Center   (United States)

Author keywords

Mantle cell lymphoma; modified R hyperCVAD; non Hodgkin's lymphoma; rituximab maintenance

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; RITUXIMAB;

ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LONG TERM CARE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80052062419     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.580404     Document Type: Article

References (29)

1. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99:842-847. (Pubitemid 28047149)
2. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-262.
3. Weisenburger DD, Armitage JO. Mantle cell lymphoma-an entity comes of age. Blood 1996;87:4483-4494. (Pubitemid 26162353)
4. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64: 190-196. (Pubitemid 30409035)
5. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
6. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89: 3909-3918.
7. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-1294. (Pubitemid 34177435)
8. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincris-tine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23: 1984-1992. (Pubitemid 46211378)
9. Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003;98:2630-2635. (Pubitemid 37509526)
10. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003;120:793-800. (Pubitemid 36315101)
11. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell auto-grafting (R-HDS regimen). Blood 2003;102:749-755. (Pubitemid 36842002)
12. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004;15:283-290. (Pubitemid 38262629)
13. Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lympho-ma: an update of a prospective study. Haematologica 2004;89:1275-1276. (Pubitemid 39390461)
14. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
15. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
16. Epner EM, Unger J, Miller T, et al. A multi center trial of hyperCVAD + rituxan in patients with newly diagnosed mantle cell lymphoma. Blood2007;110(Suppl. 1): Abstract 387.
17. Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008;19:1327-1330. (Pubitemid 351911966)
18. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-1423. (Pubitemid 44400380)
19. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-565.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
21. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
22. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614.
23. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301. (Pubitemid 44794222)
24. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochem-otherapy. J Clin Oncol2010;28(15 Suppl.): Abstract 8004.
25. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008. (Pubitemid 44920177)
26. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23:705-711. (Pubitemid 46224169)
27. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with ritux-imab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150:200-208.
28. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochem-otherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:6101-6108.
29. NCCN Guidelines. Available from:http://www.nccn.org/pro-fessionals/ physician-gls/pdf/nhl.pdf